Jeena Sikho Lifecare Ltd

AI

Jeena Sikho Lifecare Ltd

₹ 300 -0.88%
20 Nov - close price
About

Jeena Sikho Lifecare is one of the leading ayurvedic healthcare system providers in India. The company is providing healthcare services for the last ten years.

Key Points

Business Segment:[1][2]
a) Hospitals & Clinics Portfolio
Jeena Sikho Lifecare Limited (JSLL) operates a network of 119 active centers (61 hospitals + 58 clinics/day-care centres), across 23 states and 100+ cities/towns. The hospitals have 2300 operational beds, with another 445 beds in the pipeline. 561 beds were added in FY26. ompany has ~592 certified Ayurveda doctors and ~780 supporting healthcare personnel.

  • Market Cap ₹ 3,732 Cr.
  • Current Price ₹ 300
  • High / Low ₹ 809 / 277
  • Stock P/E 17.4
  • Book Value ₹ 41.6
  • Dividend Yield 1.50 %
  • ROCE 64.4 %
  • ROE 61.3 %
  • Face Value ₹ 2.00

Pros

  • Company is expected to give good quarter
  • Debtor days have improved from 49.0 to 31.8 days.
  • Company's working capital requirements have reduced from 21.2 days to 14.6 days

Cons

  • Stock is trading at 7.21 times its book value
  • Promoter holding has decreased over last 3 years: -4.24%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2024 (S) Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
100 114 116 139 174 190 222 216 224 235
75 74 86 93 96 98 121 138 132 163
Operating Profit 25 40 30 46 79 92 101 78 92 72
OPM % 25% 35% 26% 33% 45% 48% 45% 36% 41% 31%
3 3 0 0 1 1 3 3 14 -2
Interest 1 2 4 3 2 4 3 4 3 4
Depreciation 5 6 8 9 10 10 11 16 15 16
Profit before tax 21 35 18 34 69 79 89 61 88 50
Tax % 23% 25% 26% 25% 25% 25% 25% 26% 25% 26%
16 27 13 25 51 59 67 45 66 37
EPS in Rs 1.30 2.14 1.06 2.04 4.13 4.73 5.36 3.63 5.31 2.95
Raw PDF

(S): Standalone figures, shown where consolidated figures are not available.

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 Mar 2023 Mar 2025 Mar 2026 TTM
106 94 136 147 205 469 801 897
95 84 119 128 159 328 451 554
Operating Profit 11 11 17 18 46 141 351 343
OPM % 10% 11% 13% 12% 22% 30% 44% 38%
0 1 1 1 3 7 8 18
Interest 1 2 1 1 1 11 14 14
Depreciation 1 2 2 3 3 29 48 60
Profit before tax 8 8 14 15 44 108 297 287
Tax % 28% 26% 27% 26% 24% 26% 25%
6 6 10 11 34 80 222 214
EPS in Rs 0.66 0.63 1.13 1.23 2.72 6.43 17.84 17.25
Dividend Payout % 0% 0% 0% 0% 8% 17% 25%

(S): Standalone figures, shown where consolidated figures are not available.

Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 58%
TTM: 45%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 88%
TTM: 44%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: 31%
1 Year: -57%
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: 61%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 Mar 2023 Mar 2025 Mar 2026 Sep 2026
Equity Capital 0.10 0.10 0.10 10 14 25 25 25
Reserves 8 14 24 26 112 231 442 492
16 12 12 7 1 117 127 168
12 12 13 18 24 46 80 141
Total Liabilities 36 38 49 62 151 419 674 827
13 17 23 29 60 253 293 304
CWIP 0 0 0 5 1 13 3 1
Investments 0 0 0 0 5 4 110 124
23 21 26 28 86 149 269 397
Total Assets 36 38 49 62 151 419 674 827

(S): Standalone figures, shown where consolidated figures are not available.

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 Mar 2023 Mar 2025 Mar 2026
1 12 18 16 15 84 254
-11 -6 -8 -18 -33 -64 -202
7 -5 -2 -5 48 -22 -59
Net Cash Flow -2 1 8 -7 29 -2 -7
Free Cash Flow -10 6 9 -2 -15 45 221
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 35% 130% 125% 112% 50% 84% 93%

(S): Standalone figures, shown where consolidated figures are not available.

Ratios

Consolidated / View Standalone

Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 Mar 2023 Mar 2025 Mar 2026
Debtor Days 15 17 9 23 39 66 32
Inventory Days 204 315 208 149 85 78 81
Days Payable 125 168 73 109 126 106 92
Cash Conversion Cycle 94 163 143 62 -1 38 20
Working Capital Days -16 -15 -19 -12 28 28 15
ROCE % 38% 50% 52% 64%

(S): Standalone figures, shown where consolidated figures are not available.

Insights

In beta
Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Active Operational Centres
centres

Log in to view insights

Please log in to see hidden values.

Login
IPD Patient Volumes
patients
Medicine Order Volumes
lakh orders
OPD Patient Volumes
lakh patients
Beds Occupied
beds
Operational Beds
beds
SKUs in Portfolio
SKUs

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

3 Recently
Mar 2023Sep 2023Nov 2023Mar 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
66.20% 67.91% 67.91% 67.91% 65.84% 63.53% 63.53% 63.61% 63.62% 63.62% 63.62% 63.67%
0.00% 2.00% 1.79% 0.26% 4.05% 5.95% 5.91% 6.59% 6.31% 6.17% 4.78% 4.49%
0.00% 0.04% 0.00% 0.00% 0.07% 0.17% 0.18% 0.15% 0.11% 0.46% 0.36% 0.53%
33.80% 30.05% 30.30% 31.83% 30.04% 30.34% 30.38% 29.65% 29.97% 29.77% 31.24% 31.29%
No. of Shareholders 6638151,1072,7213,4235,9676,60316,36222,18125,90543,41347,872

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Annual reports

Concalls